Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

QR Code

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Saved in:

Bibliographic Details
Main Authors:	Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Format:	article
Language:	EN
Published:	Nature Portfolio 2021
Subjects:	Science Q
Online Access:	https://doaj.org/article/df7e78eab9c643b4bcc917eea8a3ff30
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
by: Carla L. Alves, et al.
Published: (2021)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
by: Olga Martínez-Sáez, et al.
Published: (2021)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
by: Abeer J. Al-Qasem, et al.
Published: (2021)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
by: Lindsey R. Pack, et al.
Published: (2021)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
by: Erin R. Scheidemann, et al.
Published: (2021)

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
by: Yibo Xue, et al.
Published: (2019)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
by: Luigi Formisano, et al.
Published: (2019)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
by: Jennifer Y. Ge, et al.
Published: (2020)

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
by: Emily Jiggens, et al.
Published: (2021)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
by: Fabin Dang, et al.
Published: (2021)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020)

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
by: Jin Zhou, et al.
Published: (2017)

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
by: Tongzheng Liu, et al.
Published: (2017)

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
by: Irina V. Kolyadina, et al.
Published: (2021)

Učinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojke
by: Nina Privšek, et al.
Published: (2021)

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
by: Shuo Qie, et al.
Published: (2019)

A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition
by: Manuel Kaulich, et al.
Published: (2021)

Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
by: Ying Ji, et al.
Published: (2020)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
by: Board Editorial
Published: (2021)

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
by: Yibo Xue, et al.
Published: (2019)

Association of Endocrine Therapy and Dementia in Women with Breast Cancer
by: Thompson MR, et al.
Published: (2021)

Metastatic breast cancer: Endocrine therapy landscape reshaped
by: Mohamad Adham Salkeni, et al.
Published: (2017)

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma
by: Andrea Magali González-Mora, et al.
Published: (2021)

Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.
by: Grzegorz Sarek, et al.
Published: (2010)

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
by: Gabriela M Wright, et al.
Published: (2021)

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition
by: Lauren E. Stopfer, et al.
Published: (2020)

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
by: Smruthi Vijayaraghavan, et al.
Published: (2017)

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
by: Jingyi Liu, et al.
Published: (2018)

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
by: Ang Gao, et al.
Published: (2018)

IgG4-related disease in endocrine practice
by: Agata Rzepecka, et al.
Published: (2018)

CDK6 inhibits white to beige fat transition by suppressing RUNX1
by: Xiaoli Hou, et al.
Published: (2018)

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy
by: Sung Pil Hong, et al.
Published: (2019)

Endocrine today

Endocrine research
Published: (1984)

Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
by: Qingfei Wang, et al.
Published: (2019)

Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
by: Muhammad Imtiaz Shafiq, et al.
Published: (2012)

Silencing CDK6-AS1 inhibits LPS-induced inflammatory damage in HK-2 cells
by: Wu Ling, et al.
Published: (2021)

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes
by: Mikkel G. Terp, et al.
Published: (2021)

Three decades of Cdk5
by: Ping-Chieh Pao, et al.
Published: (2021)

BMC endocrine disorders
Published: (2001)